Moreover, given the preliminary data’s insufficiency in SLE associated malignancies, a recent case report (57) suggests that CD19 CAR-T therapy may hold promise for SLE patients with immune thrombocytopenia (ITP). This evidence concerns the gene CD19 and systemic lupus erythematosus.